Cape Verde vs North America: Prevalence of hypertension, male
Cape Verde
45.7%
in 2019
North America
33.1%
in 2019
Cape Verde rank
35th
North America rank
33rd
Prevalence of hypertension, male over time
- Cape Verde
- North America
How they compare
Cape Verde currently reports 45.7% against 33.1% in North America, a difference of 12.6%.
That makes Cape Verde's figure about 1.4 times North America's.
Across all 30 years both countries report, Cape Verde has been ahead every year.
Cape Verde ranks 35th and North America ranks 33rd of 192 countries.
Cape Verde has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cape Verde | North America | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 45.4% | 33.0% | 12.4% | Cape Verde |
| 2000s | 47.9% | 32.8% | 15.1% | Cape Verde |
| 2010s | 47.0% | 32.9% | 14.1% | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hypertension, male, Cape Verde or North America?
- Cape Verde, at 45.7% against 33.1% in North America as of 2019.
- What is the difference in prevalence of hypertension, male between Cape Verde and North America?
- 12.6%, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and North America?
- 30 years are reported by both, from 1990 to 2019.
- How do Cape Verde and North America rank globally for prevalence of hypertension, male?
- Cape Verde ranks 35th and North America ranks 33rd of 192 countries.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Prevalence of hypertension, male (% of male adults ages 30-79). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Prevalence of hypertension, male, is the percentage of male adults ages 30-79 with hypertension (defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension). The data is age-standardized.